DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20192884

Correlation cyclooxygenase-2 expression and histopathological grading in locally advanced breast cancer

Yasser Maulidan, Salman A. Syamsu, Rudy Thabry, Zainal Abidin

Abstract


Background: Cyclooxygenase-2 (COX-2) is involved in the carcinogenesis process and tumor progression into cancer. It has been reported recently, there was a COX-2 expression at breast cancer. Patients with a high level of COX-2 expression can have a local recurrence and decrease life expectancy, and an increase of COX-2 expression in tissue likelihood has prognostic value. This study aims to correlation cyclooxygenase-2 (cox-2) expression and histopathological grading in locally advanced breast cancer patient in AW Sjahranie Hospital in Samarinda city.

Methods: This study was an observational study with crossectional design to analysis the correlation COX-2 expression and histopathological grading in patients with locally advanced breast cancer and using data analysis with the Chi-Square test.

Results: The results showed that the correlation was not significant (P>0.05), where there was no correlation of COX-2 expression with histopathological grading (P=0.221) and there was no correlation with the last condition of patients (P=0.61). Although patients with breast cancer high grade and moderate grade percentages were significantly higher in positive COX-2 than in COX-2 negative expression.

Conclusions: There were no correlation between COX-2 expression and histopathological grading and there was no significant relationship between COX-2 expression and the last condition, as evidenced by the statistical test results showing that the differences were not significant.


Keywords


Breast cancer, Cyclooxygenase-2, Histopathological grading

Full Text:

PDF

References


IARC. Globocan: Estimated Cancer Incidence, Mortality and Prevalence Worldwide In 2012. Available at: http://Www-Dep.Iarc.Fr/. Accessed 9 July 2018.

American Cancer Society. Cancer Facts and Figures 2014, 2014. Available at: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2014.html.

Kemenkes. Cancer situation: 4 February-world cancer day. 2015. Available at: http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf. Accessed 13 August 2017.

Abidin Z. Correlation Cyclooxygenase-2 (COX-2) Expression and Histopathological Grading in a Breast cancer patient in Makassar, 2016.

Manuaba TW. Guideline for managing breast cancer. Solid cancer management guide. Peraboi. Jakarta: Sagung Seto; 2010: 17-48.

Prihantono P, Hatta M, Binekada C, Sampepajung D, Haryasena H, Nelwan B, et al. Ki-67 expression by immunohistochemistry and quantitative real-time polymerase chain reaction as predictor of clinical response to neoadjuvant chemotherapy in locally advanced breast cancer. J Oncol. 2017:6209849.

Panigoro S, Hernowo BS, Purwanto H, Handojo, Haryono SJ, Arif W, et al. Guideline for management of breast cancer, 2015. Available at: http://kanker.kemkes.go.id/guidelines/Breast_Cancer.pdf. Accessed 5 July 2018.

Suyatno, Pasaribu ET. Diagnosis and Oncology surgery and Therapy. Jakarta: Sagung Seto; 2014: 17-48.

Desen W. Textbook Clinical Onkologi. 2nd ed. Jakarta: Japaries; 2011: 50-62.

Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer?. Trends Endocrinol Metab. 2005;16(7):293-9.

Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18(55):7908-16.

Divvela AK, Challa SR, Tagaram IK. Pathogenic role of cyclooxygenase-2 in cancer. J Heal Sci. 2010;56(5):502-16.

Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumor microenvironment. Carcinogenesis: 2009;30(3):377-86.

Prihantono P, Binekada C, Hatta M, Sampepajung D, Islam AA. Correlation of BCL-2 and ERα mRNA expression with the clinical chemotherapeutic response in breast cancer. J Med Sci. 2017;17(1):31-7.

Lester SC, Bae JW, Woo SU, Kim H, Kim CH. The Breast. In: Kumar V, Abbas AK, Fausto N, Aster JC. Robbin and Cothran's Pathology Basic of Diseases. 3rd ed. Philadelphia: Elsevier Saunders; 2010: 63-78.

Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354(3):270-82.

Feig BW, Berger DH, Fuhrman GM. The MD Anderson surgical oncology handbook, Lippincott Williams & Wilkins. 4th ed. New England Journal of Medicine; 2006: 60-82.

Rosen P. Invasive ductal carcinoma assesment of prognosis, morphologic prognostic markers, and tumor growth rate. New Eng J Med. 2009;360(3):250-72.

Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol. 2010;2010:270-82.

Miglietta A, Toselli M, Ravarino N, Vencia W, Chiecchio A, Bozzo F, et al. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers. Expert Opin Ther Targets. 2010;14(7):655-64.

Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62(3):632-5.

Ranger GS, Thomas V, Jewell A, Mokbel K. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res. 2004;24(4):2349-52.

Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornafel J, Wojnar A, et al. Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res. 2005;7(5):R862-70.

Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4):207.